In search of value $VERV:
Here is a look at the valuation of $VERV.
Here is a look at the valuation of $VERV.
Cash = $550 million
PCSK9 is a very competitive space. I think they could do about 30,000 patients a year at $50k per. That is about $1.5 billion in annual sales. They have to give 50% to Beam so keep $750 million.
*.1 for phase 1
= $75 million value
PCSK9 is a very competitive space. I think they could do about 30,000 patients a year at $50k per. That is about $1.5 billion in annual sales. They have to give 50% to Beam so keep $750 million.
*.1 for phase 1
= $75 million value
ANGPLT3 is a another competitive indication. I think they could do about similar in this space with $1.5 billion. They still keep only half at $750 million.
*.1 for phase 1
= $75 million value
*.1 for phase 1
= $75 million value
Based on this, I see about $700 million in valuation. They have about $61.6 million shares outstanding. That comes to $11.36. Another very expensive CRISPR company with no data to validate the science.
Loading suggestions...